# ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects

> **NCT01668524** · PHASE2 · COMPLETED · sponsor: **Altheos, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Primary Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** ATS907

## Key facts

- **NCT ID:** NCT01668524
- **Lead sponsor:** Altheos, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01668524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01668524, "ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT01668524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*